UCB continues to deliver on its growth strategy
Posted by
28-Jul-2016
It’s steady as she goes here at UCB despite the conditions outside. Our financial results for the first half of 2016 show continued growth and progress towards our goal of delivering value for patients.
We are meeting capital markets’ expectations of a steady first half of the year; a reassuring source of calm in the face of troubling external events.
The Half Year Report confirms the financial outlook for 2016 with revenue expected at approximately €4.0 – 4.1 billion, recurring EBITDA of €970 - €1,010 million, and Core Earnings Per Share in the range of €2.90 - €3.20.
In the first six months of 2016, we continued our patient value strategy which aims to deliver superior value to patients and shareholders. Revenue and net sales increased by 5% and 15 % respectively reaching € 2 billion and € 1.9 billion respectively, driven by net sales of our core products.
18% higher underlying profitability (recurring EBITDA) of €549 million reflecting continued net sales growth and a lower operating expenses ratio. Profit for the Group amounted to €316 million, a plus of 9%, of which €300 million is attributable to UCB shareholders.
We are also growing our epilepsy portfolio with the ongoing launch of a new treatment option in the EU and North America and an approval in Japan. We continue the preparations with our partner to bring a potential new drug to people living with osteoporosis and at the same time we are moving forward our promising early pipeline to deliver future breakthrough solutions for patients - to drive future growth.
New Mobile IR App – stay tuned wherever you go
You can now stay up to date with all the news and data from our Investor Relations’ team using a new mobile app. This move is part of our ongoing effort to bring you the information you need in a format that suits you.
The IR app provides you with all relevant information including a download center for HY and Annual Reports as well as press releases and presentations, stock-related data and videos, audiocast conference calls and more. Content posted on the Investor Relations section of the UCB.com website will immediately be available through the app. Download it from the Apple Store or from Google Play if you are using an Android device, and follow the next chapters in the UCB story.
Please share your feedback on this new service so we can continuously improve our offerings to you – love to hear from you! (antje.witte@ucb.com).
Wishing you a quiet summer break – enjoy life! See you again in September at multiple occasions in London, New York and perhaps Atlanta.
We are meeting capital markets’ expectations of a steady first half of the year; a reassuring source of calm in the face of troubling external events.
The Half Year Report confirms the financial outlook for 2016 with revenue expected at approximately €4.0 – 4.1 billion, recurring EBITDA of €970 - €1,010 million, and Core Earnings Per Share in the range of €2.90 - €3.20.
In the first six months of 2016, we continued our patient value strategy which aims to deliver superior value to patients and shareholders. Revenue and net sales increased by 5% and 15 % respectively reaching € 2 billion and € 1.9 billion respectively, driven by net sales of our core products.
18% higher underlying profitability (recurring EBITDA) of €549 million reflecting continued net sales growth and a lower operating expenses ratio. Profit for the Group amounted to €316 million, a plus of 9%, of which €300 million is attributable to UCB shareholders.
We are also growing our epilepsy portfolio with the ongoing launch of a new treatment option in the EU and North America and an approval in Japan. We continue the preparations with our partner to bring a potential new drug to people living with osteoporosis and at the same time we are moving forward our promising early pipeline to deliver future breakthrough solutions for patients - to drive future growth.
New Mobile IR App – stay tuned wherever you go
You can now stay up to date with all the news and data from our Investor Relations’ team using a new mobile app. This move is part of our ongoing effort to bring you the information you need in a format that suits you.
The IR app provides you with all relevant information including a download center for HY and Annual Reports as well as press releases and presentations, stock-related data and videos, audiocast conference calls and more. Content posted on the Investor Relations section of the UCB.com website will immediately be available through the app. Download it from the Apple Store or from Google Play if you are using an Android device, and follow the next chapters in the UCB story.
Please share your feedback on this new service so we can continuously improve our offerings to you – love to hear from you! (antje.witte@ucb.com).
Wishing you a quiet summer break – enjoy life! See you again in September at multiple occasions in London, New York and perhaps Atlanta.
Leave a Comment